Blog

BPC-157 ("Body Protection Compound") is a synthetic 15-amino-acid sequence derived from a fragment of a protective peptide naturally found in gastric juice. Research interest spans tendon and ligament repair, gut lining integrity, and angiogenesis.

What the literature shows

Most published work is in animal models, where BPC-157 has shown:

• Accelerated tendon-to-bone healing after surgical transection
• Faster muscle crush-injury recovery vs. control
• Protective effects on gastric and intestinal lining under NSAID stress
• Improved angiogenesis (new blood vessel formation) at injury sites

Human clinical data is still limited. The molecule is stable in gastric juice, which is why some protocols use oral administration alongside subcutaneous.

Oral vs. subcutaneous

For systemic effects (joints, tendons, soft tissue), subcutaneous near the injury site is the most-cited approach in the research. For gut-specific work, oral (sublingual or in water) is preferred since the peptide remains active through gastric exposure.

Typical research dosing

Published research protocols cite ranges of 250-500 mcg/day in 4-8-week cycles. Vial concentrations vary, calculate against your specific vial using the calculator.

Storage

Lyophilised powder: stable at room temperature for shipping, store refrigerated for long-term. Once reconstituted with bacteriostatic water: refrigerate, use within 30 days.

For laboratory research use only. Not medical advice.

All three are injectable peptides used in research on metabolic regulation, glucose handling, and body composition. All produce dramatic appetite reduction. But they differ in how many incretin receptors they engage, and that ladder of one, two, three receptors tracks closely with the reported weight-loss signal.

Semaglutide, single-receptor (GLP-1)

Semaglutide is a GLP-1 receptor agonist. It mimics the action of glucagon-like peptide-1, slowing gastric emptying, suppressing appetite, and improving insulin sensitivity. Half-life ~165 hours → typically dosed weekly.

Tirzepatide, dual-receptor (GIP + GLP-1)

Tirzepatide hits both GIP and GLP-1 receptors. The added GIP activity appears to drive stronger appetite suppression and superior weight reduction in head-to-head studies. Same weekly dosing.

Retatrutide, triple-receptor (GIP + GLP-1 + glucagon)

Retatrutide (LY3437943, Eli Lilly) adds a third arm: glucagon-receptor agonism on top of GIP and GLP-1. While GLP-1 and GIP mostly act on appetite and insulin handling, the glucagon component raises energy expenditure and supports hepatic fat mobilisation, the leading explanation for its larger weight-loss signal. It is still investigational and not approved anywhere; Phase 3 TRIUMPH-1 topline data was reported in May 2026. See the full Retatrutide research overview.

The weight-loss ladder

Across their respective trial programmes (not head-to-head, and over different durations), reported mean weight reduction rises with each added receptor:

• Semaglutide (single): ~15%, STEP trials
• Tirzepatide (dual): ~21%, SURMOUNT trials
• Retatrutide (triple): ~28-30%, Phase 3 TRIUMPH-1 (28.3% at 80 weeks; up to 30.3% at 104 weeks in a high-BMI subgroup)

Side-by-side

• Appetite suppression: all strong; the multi-receptor compounds stack additional pathways
• GI side effects (nausea, etc.): comparable in class, dose-dependent for all three
• Approval status: semaglutide and tirzepatide approved; retatrutide investigational
• Cost per mg: tends to rise from semaglutide → tirzepatide → retatrutide
• Tolerance build-up: all require titration up; rapid escalation = high nausea risk

Titration matters more than the choice

The biggest mistake in protocols is escalating too fast. Researchers typically observe better tolerability with slow titration over a 4-8 week ramp-up than with rapid escalation. Most "this didn't work" reports trace back to rapid escalation rather than the compound.

Reconstitution

All ship as lyophilised powder. A standard 5mg vial reconstituted with 2ml bacteriostatic water = 2.5mg/ml. Use the calculator to find your exact unit mark.

For laboratory research use only. Not medical advice.

Reconstitution is where good peptides get ruined. Wrong water, wrong technique, wrong storage, you've degraded a $150 vial before you've even drawn the first dose. Here's the workflow we follow.

Step 1, Use bacteriostatic water, not sterile water

Bacteriostatic water contains 0.9% benzyl alcohol, which prevents microbial growth across multiple draws over 28 days. Sterile water has nothing, single-use only, not suitable for multi-dose vials.

Step 2, Bring both to room temperature

Cold peptide powder + cold water = poor dissolution and longer mixing time. Let both sit out 15 minutes before reconstituting.

Step 3, Inject water down the side of the vial, not onto the powder

Aim the water flow against the inner wall. A direct stream onto lyophilised powder denatures fragile peptides through shear stress. Slow and angled.

Step 4, Swirl, never shake

Gently swirl the vial in your palm for 30 seconds. Do not shake. Shaking creates foam and breaks peptide bonds. Most peptides dissolve fully within 2-3 minutes of gentle swirling.

Step 5, Refrigerate immediately, label with mix date

Store at 2-8°C. Write the reconstitution date on the vial. Discard after 28 days even if some liquid remains. Keep upright, away from the freezer wall.

Common mistakes

• Reconstituting with too little water → high concentration → unit math gets unforgiving
• Leaving vial at room temp after mixing → degradation kicks in within 24h
• Pushing air through the vial repeatedly → contamination risk
• Using a 21G needle for draws → use a 27G-29G insulin syringe for accuracy

How much water?

The standard rule: pick a volume that makes your math easy. For a 10mg vial, 2ml gives 5mg/ml = 50mcg per insulin unit. Plug your numbers into the calculator to see what works for your dosing.

For laboratory research use only. Not medical advice.